Sartorius Stedim Biotech SA 2019 IR
The report highlights Sartorius Stedim Biotech's strong performance in fiscal year 2019, achieving double-digit growth with sales revenue increasing by 17.0% in constant currencies to approximately 1.44 billion euros. Underlying EBITDA rose by 23.1% to 421.5 million euros, representing a margin of 29.3%. The company expanded its global production capacities, notably in Yauco, Puerto Rico, and Aubagne, France, and acquired a majority stake in Biological Industries to strengthen its cell culture media business. Additionally, the workforce grew significantly, closing the year with over 6,200 employees.
Company: Sartorius Stedim Biotech SA
Sector: Manufacturing
Country: France
Year: 2019
Type: IR
Pages: 220
Back to company
Sartorius Stedim Biotech SA
Universal Registration Document
The report highlights Sartorius Stedim Biotech's strong performance in fiscal year 2019, achieving double-digit growth with sales revenue increasing by 17.0% in constant currencies to approximately 1.44 billion euros. Underlying EBITDA rose by 23.1% to 421.5 million euros, representing a margin of 29.3%. The company expanded its global production capacities, notably in Yauco, Puerto Rico, and Aubagne, France, and acquired a majority stake in Biological Industries to strengthen its cell culture media business. Additionally, the workforce grew significantly, closing the year with over 6,200 employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Published
Feb 17, 2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees